Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.46 -0.11 (-0.21%)
Streaming Delayed Price Updated: 2:50 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease
From Genentech
Via Business Wire
News headline image
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases ↗
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. 
Via Benzinga
News headline image
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
Via Investor's Business Daily
News headline image
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
News headline image
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis ↗
An analysis of NICE-approved drugs from 2000–2020 reveals trade-offs in NHS resource allocation, with high costs leading to a net loss of population health gains. 
Via Benzinga
News headline image
New and Updated Data for Genentech’s Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma
From Genentech
Via Business Wire
News headline image
Five-Year Results Confirm Genentech’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma
From Genentech
Via Business Wire
News headline image
The Intersection of AI, Medicine, and Stocks: A New Era of Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:AMZN),(NASDAQ:MDAI),(NYSE:MDT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
FDA Accepts Supplemental Biologics License Application for Genentech’s Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
From Genentech
Via Business Wire
News headline image
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:ISRG) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Avant Technologies’ Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy
Las Vegas, NV – December 4, 2024 – Avant Technologies, Inc.’s (OTCQB: AVAI) (“Avant” or the “Company”), partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on... 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
NVIDIA Invested in These 2 AI Stocks, Should You?
Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? ↗
Outlook Therapeutics reports ONS-5010 missed noninferiority endpoint in NORSE EIGHT trial for wet AMD but showed vision improvement and safety profile. 
Via Benzinga
News headline image
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details ↗
Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors. 
Via Benzinga
News headline image
Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results
From Genentech
Via Business Wire
News headline image
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry? ↗
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints. 
Via Investor's Business Daily
News headline image
Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology ↗
CDTX sold its Rezayo business to concentrate on its MDC-producing Cloudbreak platform which has already produced several promising drug candidates, like CD388, a very promising clinical-stage... 
Via Talk Markets
News headline image
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
News headline image
Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024
From Genentech
Via Business Wire
News headline image
New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer
From Genentech
Via Business Wire
News headline image
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Biotech Momentum Trades For The Q4 Rally ↗
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
Via Talk Markets
News headline image
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review ↗
The major indexes were mixed for the week. 
Via Investor's Business Daily
News headline image
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga
News headline image
Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations ↗
The Swiss drugmaker kept its outlook for the year despite a third-quarter sales miss. 
Via Investor's Business Daily
News headline image
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate. 
Via MarketBeat
News headline image
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
From Genentech
Via Business Wire
News headline image
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
News headline image
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer ↗
Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a... 
Via Benzinga
News headline image
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade ↗
The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.